Tela Bio, Inc. ( (TELA) ) has released its Q3 earnings. Here is a breakdown of the information Tela Bio, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
TELA Bio, Inc. is a commercial-stage medical technology company specializing in innovative soft-tissue reconstruction solutions, aiming to optimize clinical outcomes by leveraging the patient’s natural healing response while minimizing exposure to synthetic materials.
In its third quarter of 2025 earnings report, TELA Bio announced a 9% increase in revenue compared to the same period in 2024, alongside strategic moves such as the expansion of its board and the strengthening of its capital position through a new credit facility.
The company reported a revenue of $20.7 million for the quarter, driven by new customer acquisitions and international sales, despite a decrease in average selling prices for hernia products. Operating expenses decreased slightly, resulting in a reduced net loss of $8.6 million compared to $10.4 million in the previous year. TELA Bio also secured a credit facility of up to $70 million, enhancing its financial flexibility.
Looking ahead, TELA Bio projects a revenue growth of at least 16% for the full year 2025, with management expressing confidence in the strategic changes and leadership enhancements made to drive future growth and operational efficiency.